PAG
RGLS

Private Advisor Group’s Regulus Therapeutics RGLS Stock Holding History

Private Advisor Group’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$16K – 2032
2021
Q1 		$16K Buy
+1,000
New +$14.8K ﹤0.01% 1874

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Private Advisor Group's RGLS Position: Q2 2021 in Review

Private Advisor Group sold out of Regulus Therapeutics (RGLS) in Q2 2021, closing a stake of 1,000 shares — an estimated $16K sold.

Private Advisor Group first reported a position in RGLS in Q1 2021 and held it in 1 quarter. The position peaked at $16K in Q1 2021. 44 funds tracked by Wall St. Rank hold RGLS as of Q2 2021.

  • Private Advisor Group reported no remaining Regulus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Private Advisor Group sold 1,000 Regulus Therapeutics shares in Q2 2021, an estimated $16K.
  • Private Advisor Group first reported a position in Regulus Therapeutics in Q1 2021 and held it in 1 quarter.
  • Private Advisor Group's Regulus Therapeutics position peaked at $16K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2021.

Based on Private Advisor Group's 13F filing for Q2 2021, filed 12 Aug 2021.